Lexeo therapeutics inc
LXEO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
LXEO 近期報酬表現
1.67%
Lexeo therapeutics inc
-0.03%
同產業平均
0.13%
S&P500
與 LXEO 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SWTX | Springworks therapeutics inc | 2 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
CYTH | Cyclo therapeutics inc | 3 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
CMND | Clearmind medicine inc | - | 3 分 | 2 分 | - | 1 分 | |
NEXI | Neximmune inc | 2 分 | 2 分 | 4 分 | 1 分 | 1 分 | |
REPL | Replimune group inc | 2 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- SWTX Springworks therapeutics inc價值 2 分趨勢 4 分波段 2 分籌碼 3 分股利 1 分查看更多
LXEO 公司資訊
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).